Sign Up For Life Science Leader Magazine

EXECUTIVE INTERVIEWS

Versartis: Extending Action & Going It Alone

Jeff Cleland, CEO of Versartis, got into the biopharma industry early. Cleland grew up in the San Francisco Bay Area, and his parents bought him his first biotech-company stock when he was still in high school in the early 1980s.

More From Executive Interviews

THE CURRENT ISSUE

  • Biotech CEOs Express An (All-Too-Human) Risk-Taking Gene
    Biotech CEOs Express An (All-Too-Human) Risk-Taking Gene

    Anthropologists have confirmed that most Homo sapiens today carry one to four percent Neanderthal DNA. (My wife is convinced I received a larger contribution.) Potentially more damaging to our egos, Svante Paabo of the Max Planck Institute for Evolutionary Anthropology theorizes that we out-survived other Homo sapiens because of a gene mutation that makes us insanely explorative and major risk-takers.

  • Choosing To Be A Transformational Leader
    Choosing To Be A Transformational Leader

    Life is vibration. Galaxies and asteroids, oceans and continents, electrons and protons all vibrate. Managers and leaders also bring a kind of vibration to their workplace. When a leader works with their team, activities follow a predictable orbit of behavior. It is comforting to see that work and motion remain stable within known patterns and ranges.

  • Making The Decision To Implement Adaptive Trials Across A Portfolio
    Making The Decision To Implement Adaptive Trials Across A Portfolio

    The Phase 3 failure rate is hovering near 50 percent. One in five drugs requires a dose change within the first five years of marketing. The cause of these dismal statistics is rooted in the inaccuracy of the assumptions upon which trials are designed, particularly during dose selection in Phase 2.

  • Engaging Investor Interest in Biotechs: A Professional Perspective
    Engaging Investor Interest in Biotechs: A Professional Perspective

    What can executives of biotech companies working on novel treatments do to attract investors? With a professional background that has spanned the worlds of finance and biotech, I believe I have a valuable perspective on this question.

  • A 7-Step Guide To Finding The Right Strategic Investor For Your Start-Up
    A 7-Step Guide To Finding The Right Strategic Investor For Your Start-Up

    While institutional VC has been the traditional funding route for many start-ups, entrepreneurs are now more often turning to life sciences industry corporate venture capital (CVC) partners for financial and development support.

  • Biomanufacturing Industry Not Providing Employees The Tools To Succeed
    Biomanufacturing Industry Not Providing Employees The Tools To Succeed

    Biopharmaceutical manufacturing is almost always viewed as a technical discipline. But the industry is surprisingly dependent on the creativity of people who stoke its energy and direction. Indeed, as with many scientific sectors, the effectiveness of the bioprocessing industry is very much reliant on the hiring, training, and retention of high-quality staff. But with all the focus on new technologies and systems, it seems those very employees may be getting the short end of the stick.

  • A Recap On 2014 Outsourcing Trends And What To Expect In 2015
    A Recap On 2014 Outsourcing Trends And What To Expect In 2015

    2014 was an exciting year in outsourcing. Several high profile mergers and acquisitions in both the CRO and CMO world will mean some familiar names will go through big changes — Huntingdon acquired Harlan, and PRA acquired RPS in the CRO world; Patheon acquired both DSM and Gallus Biopharma, and AMRI acquired Cedarburg and OsoBio in the CMO world.

More Magazine Articles....

LIFE SCIENCE TRAINING INSTITUTE

More From LSTI
Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.

VIEW THE DIGITAL EDITION

 UPCOMING EVENTS

Identifying and Closing the Training Gap in Clinical Research

January 6, 2015
1pm-2:30pm EST, Online Training
Price:  $299 - Introductory Rate

Building Accountability on Your Clinical Teams

January 8, 2015
1pm-2:30pm EST, Online Training
Price:  $299 - Introductory Rate

Pediatric Clinical Trials: Special Considerations and Requirements

January 12, 2015
1pm-2:30pm EST, Online Training
Price:  $299 - Introductory Rate

Root Cause Analysis for GCP – A Risk Action Plan Guide

January 16, 2015
1pm-3pm EST, Online Training
See All Events